The Canadian market for Modulators of the Genital System and Sex Hormones shows a declining forecast. From 2024, the value is expected to gradually decrease from $15 USD per capita to $14.6 USD per capita by 2028. This represents a year-on-year decrease of approximately 0.67%. The compound annual growth rate (CAGR) from 2024 to 2028 is slightly negative, reflecting consistent market contraction over this period.

Future trends to watch include:

Impact of emerging generic alternatives and their effect on market prices.
Shifts in public health policies influencing demand for hormonal therapies.
Potential resilience factors such as demographic changes or technological advancements in medication delivery systems.